Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PML mutants from arsenic-resistant patients reveal SUMO1-TOPORS and SUMO2/3-RNF4 degradation pathways.

The Journal of cell biology - 2 Jun 2025

Jaffray Ellis G, Tatham Michael H, Mojsa Barbara, Plechanovová Anna, Rojas-Fernandez Alejandro, Liu Julio C Y, Mailand Niels, Ibrahim Adel F M, Ball Graeme, Porter Iain M, Hay Ronald T

Abstract excerpt

Arsenic effectively treats acute promyelocytic leukemia by inducing SUMO and ubiquitin-dependent degradation of the promyelocytic leukemia (PML)-retinoic acid receptor alpha oncogenic fusion protein. However, some patients relapse with arsenic-resistant disease because of missense mutations in PML. To determine the mechanistic basis for arsenic resistance, PML-/- cells were reconstituted with YFP fusions of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Arsenic
Share to Leukemia, Promyelocytic, Acute

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Promyelocytic Leukemia Protein

Share to Proteolysis

Share to Small Ubiquitin-Related Modifier Proteins

Share to SUMO-1 Protein

Share to Sumoylation

Share to Ubiquitins

Source

Open in PubMed Open full text

Identifiers

PMID: 40239066
DOI: 10.1083/jcb.202407133
PMCID: PMC12002637

Genes

PML
RNF4
TOPORS
SUMO1
SUMO2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PML mutants from arsenic-resistant patients reveal SUMO1-TOPORS and SUMO2/3-RNF4 degradation pathways.PMID 40239066Read ↗

PML mutants resistant to arsenic induced degradation fail to generate the appropriate SUMO and ubiquitin signals required for RNF4 and p97 recruitmentSemantic proximity Read ↗

Acute promyelocytic leukemia, arsenic, and PML bodiesSemantic proximity Read ↗

SUMO deconjugation is required for arsenic-triggered ubiquitylation of PML.Semantic proximity Read ↗

Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatmentSemantic proximity Read ↗

Requirement of PML SUMO interacting motif for RNF4- or arsenic trioxide-induced degradation of nuclear PML isoforms.Semantic proximity Read ↗

The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA.Semantic proximity Read ↗

Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.Semantic proximity Read ↗

Varying responses of PML-RARA with different genetic mutations to arsenic trioxideSemantic proximity Read ↗

Concerted SUMO-targeted ubiquitin ligase activities of TOPORS and RNF4 are essential for stress management and cell proliferationSemantic proximity Read ↗

FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemiasSemantic proximity Read ↗

Arsenic-induced PML targeting onto nuclear bodies: Implications for the treatment of acute promyelocytic leukemiaSemantic proximity Read ↗

PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.